keyword
MENU ▼
Read by QxMD icon Read
search

Leukotriene antagonists

keyword
https://www.readbyqxmd.com/read/29114905/leukotriene-receptor-antagonism-may-not-be-effective-in-atopic-dermatitis-treatment-after-all
#1
W K Chin
WHAT IS KNOWN AND OBJECTIVE: Literature evidence suggests leukotriene involvement in the pathogenesis of atopic dermatitis. This article aimed to discuss whether the off-label use of montelukast, a leukotriene receptor antagonist, is justifiable for the treatment of atopic dermatitis. COMMENT: Most non-randomized studies supported the use of montelukast for atopic dermatitis treatment. However, evidence from these studies should be interpreted with caution as it is relatively weak due to the absence of randomization, control groups and blinding processes, subjecting the results to high risk of selection and reporting biases...
November 7, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29114894/lack-of-long-term-add-on-effect-by-montelukast-in-postoperative-chronic-rhinosinusitis-patients-with-nasal-polyps
#2
Laura Van Gerven, Cristobal Langdon, Arturo Cordero, Sara Cardelús, Joaquim Mullol, Isam Alobid
OBJECTIVES/HYPOTHESIS: Eosinophils and mast cells are among the key cells in inflammatory diseases like chronic rhinosinusitis (CRS) and asthma. Leukotriene antagonists have proven to be effective in the treatment of asthma, but data about their efficacy in CRS are scarce, whereas data on montelukast as an add-on treatment to intranasal corticosteroids (INCS) in a postoperative setting are completely lacking. STUDY DESIGN: Prospective, randomized, open-label trial...
November 8, 2017: Laryngoscope
https://www.readbyqxmd.com/read/29090333/resolvin-e1-e2-ameliorate-lipopolysaccharide-induced-depression-like-behaviors-via-chemr23
#3
Satoshi Deyama, Kento Shimoda, Hiroe Suzuki, Yuka Ishikawa, Kohei Ishimura, Hayato Fukuda, Natsuko Hitora-Imamura, Soichiro Ide, Masamichi Satoh, Katsuyuki Kaneda, Satoshi Shuto, Masabumi Minami
RATIONALE: Resolvins are bioactive lipid mediators that are generated from docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). We recently demonstrated that the DHA-derived resolvins D1 and D2 exert antidepressant effects. However, whether the EPA-derived resolvins E1 (RvE1) and E2 (RvE2) produce antidepressant effects is not clear. OBJECTIVES: We examined the antidepressant effects of RvE1/RvE2 in a murine lipopolysaccharide (LPS)-induced depression model using the tail suspension and forced swim tests...
October 31, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/29079387/management-of-allergic-rhinitis-a-review-for-the-community-pharmacist
#4
REVIEW
J Russell May, William K Dolen
PURPOSE: Allergic rhinitis is a highly prevalent disease affecting the quality of life of millions of North Americans. The management of allergic rhinitis includes allergen avoidance, pharmacotherapy, and immunotherapy. Current pharmacologic options include oral and intranasal antihistamines, intranasal corticosteroids, oral and intranasal decongestants, oral and intranasal anticholinergics, and leukotriene receptor antagonists. Second-generation oral antihistamines and intranasal corticosteroids are the mainstays of treatment, with practice guidelines recommending intranasal corticosteroids as first-line treatment for moderate to severe allergic rhinitis...
October 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29072660/-the-role-of-a-leukotriene-receptor-antagonist-in-the-restoration-of-the-nasal-breathing-in-the-patients-presenting-with-polypous-rhinosinusitis
#5
T A Mashkova, A B Mal'tsev, A I Nerovny, L S Bakulina
The present study was designed to investigate the clinical. laboratory, and morphological characteristics of the nasal obstruction process. It included 87 patients presenting with polypous rhinosinusitis. The dynamics of the serum leukotriene C4 (LTC4) level in the patients and the morphological changes in their polypous tissue suggested the existence of the pronounced exudative phase of allergic inflammation and provided a basis for the use of the leukotriene receptor antagonist in the form of the sodium montelucast tablets for the treatment of nasal obstruction...
2017: Vestnik Otorinolaringologii
https://www.readbyqxmd.com/read/29047178/the-effect-of-montelukast-on-early-life-wheezing-a-randomized-double-blinded-placebo-controlled-study
#6
Ozlem Keskin, Ebru Arik Yilmaz, Christine Motzkus, Cansin Sackesen, Craig M Lilly, Omer Kalayci
BACKGROUND: Cysteinyl-leukotrienes are increased in the airways of infants with virus-associated wheezing. We aimed to determine the effects of a cysteinyl-leukotriene-1 receptor antagonist on symptoms during an early-life wheezing illness and to investigate the factors that affect the response to this drug. METHOD: This placebo-controlled double-blinded randomized controlled trial recruited children aged 3-36 months with wheezing illness and randomized to active drug or placebo for 56 days...
October 19, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29042030/recent-advances-in-clinical-development-of-leukotriene-b4-pathway-drugs
#7
REVIEW
L Bhatt, K Roinestad, T Van, E B Springman
The LTB4 pathway is an attractive target for therapeutic drug development. Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the rate limiting enzyme in the production of LTB4. An initial wave of effort culminated in the 1990s. Over the past 15 years, a second wave of more selective drug candidates, including at least 5 BLT antagonists and 6 LTA4H inhibitors, have reached Phase 2 clinical trials. Despite the extensive efforts to discover and develop LTB4 pathway targeting drugs, only one has reached the market to date...
October 2017: Seminars in Immunology
https://www.readbyqxmd.com/read/29038166/why-and-how-to-step-down-chronic-asthma-drugs
#8
REVIEW
Michael R Gionfriddo, John B Hagan, Matthew A Rank
Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose...
October 16, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29031615/the-leukotriene-receptor-antagonist-pranlukast-attenuates-airway-remodeling-by-suppressing-tgf-%C3%AE-signaling
#9
Jung Hur, Ji Young Kang, Chin Kook Rhee, Young Kyoon Kim, Sook Young Lee
BACKGROUND/OBJECTIVE: Asthma is a chronic airway disease characterized by airway eosinophilic inflammation and remodeling, which are associated with a loss in lung function. Although both contribute significantly to asthma pathogenesis, mechanistic studies and drug discovery have focused on inflammatory targets. In this study, we investigated the effect of the leukotriene receptor antagonist pranlukast on allergic airway inflammation and remodeling in vivo and in vitro. METHOD: Four groups of female BALB/c mice (control; ovalbumin [OVA]-sensitized and -challenged; dimethyl sulfoxide [DMSO]-treated OVA; and pranlukast-treated OVA) were examined...
October 12, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29031394/the-role-of-cysteinyl-leukotrienes-and-their-receptors-in-refractory-nasal-polyps
#10
Jintao Du, Luo Ba, Jiao Zhou, Lingyu Yu, Ruowu Liu, Jie Zhang, Feng Liu, Junming Xian, Shixi Liu, Yafeng Liu
Leukotriene signaling is essential in many diseases, including asthma, allergic rhinitis, atherosclerosis and inflammatory bowel disease. Nevertheless, the expression of cysteinyl leukotrienes (CysLTs) and its receptors (CYSLTRs) in different types of nasal polyps (NPs), and the role of their antagonist in the treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) are not well understood. The following study investigates the expression of CysLTs and CYSLTRs in different types of NPs, as well as the role of leukotriene receptor antagonist (montelukast) in refractory NPs...
November 2017: Prostaglandins, Leukotrienes, and Essential Fatty Acids
https://www.readbyqxmd.com/read/28971612/adverse-drug-reactions-of-montelukast-in-children-and-adults
#11
Meindina G Haarman, Florence van Hunsel, Tjalling W de Vries
Montelukast, a selective leukotriene receptor antagonist, is recommended in guidelines for the treatment of asthma in both children and adults. However, its effectiveness is debated, and recent studies have reported several adverse events such as neuropsychiatric disorders and allergic granulomatous angiitis. This study aims to obtain more insight into the safety profile of montelukast and to provide prescribing physicians with an overview of relevant adverse drug reactions in both children and adults. We retrospectively studied all adverse drug reactions on montelukast in children and adults reported to the Netherlands Pharmacovigilance Center Lareb and the WHO Global database, VigiBase(®) until 2016...
October 2017: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/28965921/therapeutic-approaches-of-asthma-and-copd-overlap
#12
REVIEW
Mitsuko Kondo, Jun Tamaoki
Asthma and COPD overlap (ACO) is an important clinical phenotype, due to the low-health-related quality of life (QOL), rapid decline in lung function, frequent exacerbation, and high economic burden. However, no large-scaled therapeutic trials of ACO have been conducted. At present, ACO is treated according to asthma/COPD guidelines. The goals of ACO treatment are to relieve symptoms and improve QOL and lung functions. Treatment must also prevent disease progression, airway remodeling, exacerbation, complications, and comorbidities...
September 28, 2017: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/28951192/role-of-prostaglandin-e2-in-bronchoconstriction-triggered-cough-response-in-guinea-pigs
#13
Akihito Okazaki, Johsuke Hara, Noriyuki Ohkura, Masaki Fujimura, Tamami Sakai, Miki Abo, Nobuyuki Katayama, Kazuo Kasahara, Shinji Nakao
A feature of cough variant asthma is a heightened cough response to bronchoconstriction. The mediators of this response are unknown. This study was designed to elucidate the role of lipid mediators in bronchoconstriction-triggered cough response in an experimental animal model. We examined the influence of bronchoconstriction on cell components and mediators including prostaglandin E2 (PGE2) in bronchoalveolar lavage fluid (BALF). We studied the cough response to bronchoconstriction (CRB) by measuring the correlation between the increase in enhanced pause (Penh), an index of bronchoconstriction, and cough counts induced by methacholine (Mch) inhalation in conscious guinea pigs...
September 22, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28947037/physicians-preference-for-controller-medication-in-mild-persistent-asthma
#14
Arzu Bakirtas, Ali Kutlu, Ayse Baccioglu, Ferda Oner Erkekol, Sevim Bavbek, Omer Kalayci
BACKGROUND: Although the asthma guidelines recommend inhaled corticosteroids(ICS) or leukotriene receptor antagonists-(LTRAs) for the treatment of mild persistent asthma, factors governing the physicians' preference are unknown. We aimed to investigate the preference of physicians for the controller medication and the factors governing their choice. METHODS: A self-administered questionnaire composed of 16 questions that aimed to determine the preference of the physicians for the first choice controller medication in mild persistent asthma and physician and patient related factors that may be associated with this selection was e-mailed to the members of the Turkish National Society of Allergy and Clinical Immunology and distributed to participants in the 21st congress...
October 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28932020/role-of-the-cysteinyl-leukotrienes-in-the-pathogenesis-and-progression-of-cardiovascular-diseases
#15
REVIEW
Francesca Colazzo, Paolo Gelosa, Elena Tremoli, Luigi Sironi, Laura Castiglioni
Cysteinyl leukotrienes (CysLTs) are potent lipid inflammatory mediators synthesized from arachidonic acid, through the 5-lipoxygenase (5-LO) pathway. Owing to their properties, CysLTs play a crucial role in the pathogenesis of inflammation; therefore, CysLT modifiers as synthesis inhibitors or receptor antagonists, central in asthma management, may become a potential target for the treatment of other inflammatory diseases such as the cardiovascular disorders. 5-LO pathway activation and increased expression of its mediators and receptors are found in cardiovascular diseases...
2017: Mediators of Inflammation
https://www.readbyqxmd.com/read/28928804/efficacy-of-a-leukotriene-receptor-antagonist-for-pediatric-cedar-pollen-allergy-complicated-by-asthma
#16
Shigemi Yoshihara, Yutaka Kikuchi, Mari Saitou, Susumu Yanagawa, Noriko Kanno, Hiroshi Igarashi, Hironobu Fukuda, Akiko Iimura, Toshio Abe, Yumi Yamada, Tamotsu Andou, Osamu Arisaka
Leukotriene receptor antagonists (LTRAs) are identified as a monotherapy for asthma and allergic rhinitis; however, their use in children for treatment of these diseases has not been examined. Accordingly, the present study investigated the efficacy of pranlukast dry syrup for children with both pollinosis and asthma. The subjects were children receiving treatment for asthma who were also diagnosed with cedar pollen allergy. Patients were divided into a group that received continuous treatment with pranlukast (group A; n=20) and a group that commenced add-on treatment for pollinosis following the onset of symptoms (group B; n=20)...
October 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28919798/comparative-effects-of-the-%C3%AF-3-polyunsaturated-fatty-acid-derivatives-resolvins-e1-and-d1-and-protectin-dx-in-models-of-inflammation-and-pain
#17
Flávia Cs Fonseca, Ricardo M Orlando, Regina Mm Turchetti-Maia, Janetti Nogueira de Francischi
PURPOSE: Specialized pro-resolving lipid mediators (SPMs), also known as lipoxins, resolvins (Rvs), protectins and maresins, have been implicated in the resolution of the inflammatory process. However, a systematic comparison of their activity in the relief of inflammation and pain models is still lacking. MATERIALS AND METHODS: The effects of Rvs E1 and D1 and protectin DX (PDX) were assessed in rat paws inflamed by the standard proinflammatory stimulus carrageenan or by histamine, 5-hydroxytryptamine, substance P or prostaglandin E2...
2017: Journal of Inflammation Research
https://www.readbyqxmd.com/read/28913986/chronic-spontaneous-urticaria-pathogenesis-and-treatment-considerations
#18
REVIEW
Allen P Kaplan
The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H₁-receptor blockers are typically employed up to 4 times a day. First-generation antihistamines, such as hydroxyzine or diphenhydramine (Atarax or Benadryl), were employed similarly in the past. Should high-dose antihistamines fail to control symptoms (at least 50%), omalizumab at 300 mg/month is the next step...
November 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/28884989/hydroxychloroquine-in-the-treatment-of-anti-histamine-refractory-chronic-spontaneous-urticaria-randomized-single-blinded-placebo-controlled-trial-and-an-open-label-comparison-study
#19
T Boonpiyathad, A Sangasapaviliya
Background. The management of anti-histamine refractory chronic spontaneous urticaria (CSU) has poorly defined therapeutic options. Some patients with CSU respond poorly to a fourfold increase in dosage of H1-anti-histamines treatment. Aim. The objective of this study was to determine the effect of an adjunct treatment of hydroxychloroquine (HCQ) on remission rate and reduction of urticarial symptoms. Methods. Sixty subjects with anti-histamine refractory CSU were randomly assigned to 400 mg of HCQ daily or placebo for 12 weeks in a single blind placebo controlled trial...
September 2017: European Annals of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28881155/seasonal-patterns-of-asthma-medication-fills-among-diverse-populations-of-the-united-states
#20
Kedir N Turi, Tebeb Gebretsadik, Rees L Lee, Tina V Hartert, Amber M Evans, Cosby Stone, Nicholas M Sicignano, Ann C Wu, Carlos Iribarren, Melissa G Butler, Edward Mitchel, James Morrow, Emma K Larkin, Pingsheng Wu
OBJECTIVE: Nonadherence to controller and overuse of reliever asthma medications are associated with exacerbations. We aimed to determine patterns of seasonal asthma medication use and to identify time period(s) during which interventions to improve medication adherence could reduce asthma morbidity. METHODS: We conducted a retrospective cohort study of asthmatics 4-50 years of age and enrolled in three diverse health insurance plans. Seasonal patterns of medications were reported by monthly prescription fill rates per 1000 individuals with asthma from 1998 to 2013, and stratified by healthcare plan, sex, and age...
September 7, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
keyword
keyword
19644
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"